Could timing of cancer treatments be the missing link in delivery of cancer therapies? Sounds too simple to be true? Two cancer researchers Martin Ashdown & Brendon Coventry are “immunological explorers” who not only unearthed a buried “treasure”; but they have also created a map for other innovative cancer “explorers” to follow. The “treasure” is a cancer drug used for more than 20 years that is now providing oncologists with new information about how to best help patients achieve complete remission. The drug called interleukin-2, is providing cancer researchers with something akin to how the “Rosetta Stone” was used to unlock historical script; the outcome; mapping the immune cycle! Join me with guest Martin Ashdown on Navigating the Cancer Maze to hear the story of this amazing breakthrough. Learn how you can access info about your immune cycle to assist cancer treatment efficacy. Please email me at firstname.lastname@example.org
Martin Ashdown – Martin Ashdown is a Melbourne based scientist, Research Fellow at the Faculty of Medicine University of Melbourne. Martin has made the observation that the immune response in the late stage cancer patient is oscillating repeatedly over an approximate seven day period or cycle. This observation may have profound implications for the timed delivery of various therapies, which via immune modulation may increase complete response rates, reduce toxicity and substantially reduce the cost of treatment. Martin has co-designed trials at international institutions and presented at international conferences advocating monitoring patients prior to treatment and accurately timing therapy as pulses. This technique, known as Immune Synchronization is believed to already happen accidentally is those patients who successfully respond to therapy with a complete response. Martin and colleagues suggest that the drugs and resources to successfully treat cancer are already here, but need to be used more accurately.
Return to Home – for more uplifting Cancer Podcasts with Grace Gawler & Guests